---
title: "Midway Evaluation"
subtitle: "Dept. of Clinical Science II <br/> University of Bergen"  
author: 
  - "&#x1F60E; Jonelle Dickow Villar"
date: "November 25, 2021"
output:
  xaringan::moon_reader:
    css: [xaringan-themer.css, yellow_dots.css, extra.css]
    nature:
      slideNumberFormat: "%current%"
      highlightStyle: github
      highlightLines: true
      ratio: 16:9
      countIncrementalSlides: true
---

```{r setup, include=FALSE}
options(htmltools.dir.version = FALSE)
knitr::opts_chunk$set(
  fig.width=9, fig.height=3.5, fig.retina=3,
  out.width = "100%",
  cache = FALSE,
  echo = TRUE,
  message = FALSE, 
  warning = FALSE,
  hiline = TRUE
)
library(fontawesome)
library(tidyverse)
library(xaringan)
library(here)

```

```{r xaringan-themer, include=FALSE, warning=FALSE}
library(xaringanthemer)

dark_yellow <- "#EFBE43"
light_yellow <- "#FDF7E9"
gray <- "#333333"
blue <- "#4466B0"

style_duo(
  # colors
  primary_color = light_yellow,
  secondary_color = dark_yellow,
  header_color = gray,
  text_color = gray,
  code_inline_color = colorspace::lighten(gray),
  text_bold_color = colorspace::lighten(gray),
  link_color = blue,
  title_slide_text_color = blue,

  # fonts
  header_font_google = google_font("Martel", "300", "400"),
  text_font_google = google_font("Lato"),
  code_font_google = google_font("Fira Mono")  
)



```

```{r xaringanExtra, echo=FALSE, warning=FALSE}

library(xaringanExtra)
xaringanExtra::use_logo("UiBlogoMED_gray_v_Eng.png",
                        width = "250px",
                        height = "250px",
                        position = xaringanExtra::css_position(top = "2em", right = "2em"))
                     

xaringanExtra::use_tile_view()

```


```{css extra.css, echo=FALSE}

.small { 
  font-size: 0.75em
}  

.bitty { 
    font-size: 1.25em;
}

.enlarge { 
    font-size: 1.5em;
}

.fade {
  opacity: 0.66;
}

```


---

class:hide_logo

###**An Epigenetic Study of Treatment Effects and Environmental Factors in Schizophrenia and Bipolar Disorder**<br><br>

.large[.right[
**Principal Supervisor**: St√©phanie Le Hellard, UiB<br><br>
**Co-Supervisors**: Anne-Kristin Stavrum, UiB,<br><br>
                  Tetyana Zayats, Broad Institute, USA<br><br>
                  Ingrid Melle, UiO<br><br><br>
                  July 1, 2019 - June 30, 2023
]]              

---

###Plan for this talk <br> <br />
###- Objectives <br />
###- Methods <br />
###- Status of project <br />


---

###Objectives of this PhD work <br />

###**General aim**
.bitty[
 - To identify epigenetic marks associated with psychosis and treatment effects <br />
]

###**Specific aims**
.bitty[
1. Association of SCZ vs. controls on cell-type proportions is impacted by time-of-blood draw <br> <br />
2. Common and specific effects of antipsychotic drugs in psychosis <br> <br />
3. Disorder specific effects of SCZ vs. BPD <br> <br />
4. Evaluate whether any specific effects are associated with developmental timing 
]  
---

class: hide_logo

background-image: url(Smigielski.png)
background-position:cover
background-size: 750px

.footnote[Smigielski, _et al_, Molecular Psychiatry, 2020]



## **Epigenetics**



---


###Epigenetics in psychiatric disorders  <br> <br> 

.bitty[
- Development: prenatal environmental factors _in utero_ <br> <br>
- MZ twins discordant for SCZ/BPD show DNAm associated differences (Dempster, _et al._, 2011) <br> <br>
- Dynamic; influenced by many environmental exposures - trauma, adversity, life-style <br> <br>
- DNAm profiles associated with brain volume, structure and function; social & cognitive function (Starnawska & Demontis, 2021)<br> <br>
- Changes overtime as a function of age and chronicity of the disorder 
]


---

###Circadian rhythms and "chrono-epigenetics" <br> <br> 

.bitty[
- Circadian rhythms are disrupted in serious mental disorders  <br> <br>
- Co-evolution of methyl cycle and circadian clocks (Fustin, _et al._, 2020) <br> <br>
- DISC1 in SCZ regulates stability of clock gene BMAL1 (Lee, _et al._, 2021)
]

---

class: hide_logo

background-image: url(time-naive.png)
background-position:50% 60%
background-size: 615px

.footnote[Oh, E. & Petronis, Nature Reviews Genetics, 2021]



### **Time-naive DNAm measurement**


---

class: hide_logo

background-image: url(time_sensitive.png)
background-position:50% 60%
background-size: 615px

.footnote[Oh, E. & Petronis, Nature Reviews Genetics, 2021]

### **Time-sensitive DNAm measurement**


---


background-image: url(Daylight_EG.png)
background-position: 60% 75% 
background-size: 515px

class: left, top

###Project 1
###Does time-of-blood draw impact the association of SCZ vs controls on cell-type proportions?

.pull-right[.footnote[Eug√®ne Gabritschevsky, _Untitled_,1947]]


---


###Methods <br> <br>

.bitty[
1. Selected European SCZ cases & controls with recorded time-of-blood draw (n=729) <br> <br>
1. Samples matched for age and gender <br> <br>
1. Estimated cell-type proportions from DNAm data (*Salas, _et al._, 2018*) <br> <br>
1. Compared linear regression models when adjusting for blood draw time.  <br> <br>
1. Compared full day vs half day <br> <br>
1. Sub-analyses: Neutrophil-to-lymphocyte ratio and Medication-free SCZ
]
---

background-image: url(2021_08_05_Histogram_n729.png)
background-position: 50% 90% 
background-size: 425px

class: left, top
###Case-Control recorded blood draws (n=729)


- Model 1: Cell-type proportions ~  Case_Control + Age + Sex + Smoking_score + Methbatch + ùú∫
- Model 2: Cell-type proportions ~ Case_Control + Age + Sex + Smoking_score + Methbatch + Hours_from_baseline + ùú∫


---


background-image: url(2021_09_04_Table.CorrectPvalsTeal.png)
background-position: 25% 45% 
background-size: 400px

class: top left hide_logo
###Results

.pull-right[

###Full day

.bitty[
- P-values reduced significance in Model 2
- Effect sizes diminished in Model 2
]

###Half day

.bitty[
- P-values no change 
- Effect sizes no change
]
]

---


background-image: url(1947superJumbo.jpg)
background-position: 60% 75%
background-size: 525px

class: left, top
###Project 2
###Common and specific effects of antipsychotics associated with psychosis

.pull-left[
.footnote[Eug√®ne Gabritschevsky, _Untitled_,1947]
]

---

background-image: url(Aringhieri2.jpg)
background-position: 60% 75%
background-size: 775px

class: left, top

###Antipsychotics and corresponding receptors

.footnote[Aringhieri _et al_, Pharmacology & Therapeutics, 2018]

---

### Pharmacoepigenetic findings in psychiatry 

.bitty[
- Early stages <br> <br>
  - Study design, technology, patient population, lack of replication <br> <br>
  - No uniform identification of hyper- or hypo-methylation (i.e. _COMT_, _5-HTT_, _HTR2A_) (Burghardt, _et al._, 2020, Zhou _et al_, 2021) <br> <br>
  - Lacking studies of AP monotherapy (Burghardt, _et al._, 2020) <br> <br>
  - DNAm associated with both the pathology and treatment (Jaffe, _et al._, 2016) <br> <br>
  - Tissue issue - relevance of peripheral blood (Bakulski, _et al._, 2016)
]
---

background-image: url(rho_table2.png)
background-position: 50% 70%
background-size: 800px


###Correlation blood-brain DNAm  <br> 

.bitty[
- Technological improvements:  450K vs. EPIC (850K)  
- Blood / live brain-tissue samples:      r = 0.86 
- CpGs identified within promoter: r = 0.92
]


.footnote[Braun _et al._, Translational Psychiatry, 2019]

---



###Methods <br> 

.bitty[
1. Select European SCZ, BPD and MDD cases being treated with antipsychotics <br> <br>
1. Select samples with blood drawn within 4 months of interview date <br> <br>
1. **Common**: Compare AP-use vs non AP-use   <br> <br>
1. **Specific**: Contrast mono-therapy against non-target polytherapy.  <br> <br>
1. Model: DNAm ~ Psychosis_Cases + Age + Sex + Smoking + eCells + Technical + ùú∫<br> <br>
1. Identify CpGs (_limma_), associated genes (_Illumina annotation), and DMRs (_Demarcate_) <br> <br>
1. GSEA and pathway analysis (GREAT) <br> <br>

]


---

###Preliminary distributions - four targets mono-therapies 

class: left, top


###Identify DNA methylation associated with treatment effects of antipsychotics in psychosis 

###- Aripiprazole - partial agonism D2/3 
###- Olanzapine -  5-HT2A H1 a1, M1
###- Quetiapine - receptor affinity D2/3  H1
###- Risperidone - receptor affinity 5-HT2A relative to D2/3 blockade

---



background-image: url(Sans-titre-1949-Gouache-sur-papier.jpg)
background-position: 50% 70%
background-size: 525px


class: left, top 

###Project 3
###Identify differential DNA methylation in SCZ versus Bipolar

.pull-left[
.footnote[Eug√®ne Gabritschevsky, _Untitled_,1949]
]



---
###Characteristics 

###Similarities

.bitty[
- Early age of onset ~ 20-30 years old <br> <br>
- Heritability ~ 80% <br> <br>
- Periods of stability and relapse <br> <br>
- Dysregulated circadian rhythmicity: both a trait and state marker (Walker II, _et al._, 2020) <br> <br>
- Medication primary form of treatment 
]

### Differences 

.bitty[
- Polygenic risk score (PRS) differed significantly (Ruderfer, _et al., 2014) <br />
- Two genome-wide significant SNPs (BPD&SCZ Working Group of the PGC., 2018) <br />
- Clinical differences behavioral, cognition, intelligence (Reichenberg,_et al._, 2009) <br /> 

- 
]
---

class: top left
### **Clinical Course of SCZ and BPD**

.pull-left[
![](ClinicalCourse_adapt.png)
]

.pull-right[
![](course_BPD.jpeg)
]


.pull.left[.footnote[McCutcheon, _et al.,_ JAMA Psychiatry, 2020]]
.pull-right[.footnote[Elanjithara, _et al.,_ 2011]]


---

IGNF
Caspi? 

---
###Methods <br> <br>

.enlarge[
1. Select SCZ and BPD cases from Project 2 <br> <br>
1. Extract CpGs associated with antipsychotics from Project 2 <br> <br>
1. Model: DNAm ~ SCZ_BDP + Age + Sex + Smoking + Cells + Technical +ùú∫
1. GSEA and pathway analyses (GREAT) <br> <br>
1. Compare findings to GWAS 
]

---

### References

.small[
Aringhieri, _et al_, Molecular targets of atypical antipsychotics: From mechanism of action to clinical differences, _Pharmacology & Therapeutics_, 2018.

Bakulski, _et al._, Epigenetic Research in Neuropsychiatric Disorders: the ‚ÄúTissue Issue‚Äù, _Curr Behav Neurosci Rep., 2016.

Braun, _et al._, Genome-wide DNA methylation comparison between live human brain and peripheral tissues within individuals, _Translational Psychiatry_, 2019.

Caspi, _et al._, Longitudinal Assessment of Mental Health Disorders and Comorbidities Across 4 Decades Among Participants in the Dunedin Birth Cohort Study, _JAMA Network Open_, 2020.

Dempster, _et al._, Disease-associated epigenetic changes in monozygotic twins discordant for schizophrenia and bipolar disorder, _Human Molecular Genetics_, 2011.

Elanjithara, _et al._, Treatment of early stages of bipolar disorder, _Advances in Psychiatric Treatment_, 2011.

Fustin, _et al._, Methylation deficiency disrupts biological rhythms from bacteria to humans, _Communications Biology_, 2020.

Jaffe & Irizarry, Accounting for cellular heterogeneity is critical in epigenome-wide association studies, _Genome Biology, 2014.

Lappalainen & Greally, Associating cellular epigenetic models with human phenotypes, _Nature Rev Genetics_, 2017.

Lee, _et al._, Disrupted-in-schizophrenia 1 enhances the quality of circadian rhythm by stabilizing BMAL1, _Translational Psychiatry_, 2021.

McCutcheon, _et al._, Schizophrenia - An Overview, _JAMA Psychiatry_, 2019.

Oh & Petronis, Origins of human disease: the chrono-epigenetic perspective _Nature Rev Genetics_, 2021.

Rakyan, _et al._, Epigenome-wide association studies for common human diseases, _Nature Rev Genetics_, 2011.

Salas, _et al._, An optimized library for reference-based deconvolution of whole-blood biospecimens assayed using the Illumina HumanMethylationEPIC BeadArray, _Genome Biology_, 2018. 

Smigielski, _et al_, Epigenetic mechanisms in schizophrenia and other psychotic disorders: a systematic review of empirical human Ô¨Åndings, _Molecular Psychiatry_, 2020.

Walker II, _et al._, Circadian rhythm disruption and mental health, _Translational Psychiatry_, 2020.

Wei, _et al._, Ten Years of EWAS, _Advanced Science_, 2021.

]

---
### References


---
class: center, top

background-image: url(Martens_lab_2021.jpg)
background-position: 10% 70%, 20% 10%
background-size: 600px

# Acknowledgements

.pull-right[
**Supervisor Prof. St√©phanie Le Hellard**<br><br>
**Co-Supervisor Dr. Anne-Kristin Stavrum**<br><br>
**Colleagues in The Martens Group**<br><br><br>
[`r fa_i("twitter")` @jdvillar](https://twitter.com/jdvillar)
]]


---


class: left top inverse 
##Conclusion of the public event <br> <br>

##Happy to take questions



---


background-image: url(ECT3.png)
background-position: 50% 65%
background-size: 600px

class: left top 
##Formal training components completed

---

background-image: url(posters3.png)
background-position: contain
background-size: 800px


class: left top 
##FORMIDL901 to be completed

---

background-image: url(Plan3.png)
background-position: 50% 65%
background-size: 675px

class: left top 
##Plan for project completion

---


class: left top 

###Technical Challenges <br>

.bitty[
- Currently no standardized pipeline for QC and EWAS (including DMRs and pathway analyses). <br><br>
- EPIC probes biased for cancer genes. <br> <br>
- EWAS literature (2011- 2020): <br><br>
    - 47% pertains to Illumina 450K; <br><br>
    - < 7% to EPIC (Wei _et al.,_ 2021) <br><br>
- Small sample sizes may lack power. <br> <br>
- Large meta-analyses are challenged with different study designs or methods. 
]
 

---

class: left top 

###Scientific Challenges <br> <br>

.bitty[
- We can¬¥t control for all environmental factors. <br> <br>
- The data available to us is derived from one blood sample. <br> <br>
- Small sample sizes assayed on the chip provide analysis challenges (i.e. singularity) <br> <br>

]











